Cargando…
Plasma metabolomic profile varies with glucocorticoid dose in patients with congenital adrenal hyperplasia
Glucocorticoid replacement therapy is the mainstay of treatment for congenital adrenal hyperplasia (CAH) but has a narrow therapeutic index and dose optimisation is challenging. Metabolomic profiling was carried out on plasma samples from 117 adults with 21-hydroxylase deficiency receiving their usu...
Autores principales: | Alwashih, Mohammad A., Watson, David G., Andrew, Ruth, Stimson, Roland H., Alossaimi, Manal, Blackburn, Gavin, Walker, Brian R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5719028/ https://www.ncbi.nlm.nih.gov/pubmed/29213133 http://dx.doi.org/10.1038/s41598-017-17220-5 |
Ejemplares similares
-
Acute interaction between hydrocortisone and insulin alters the plasma metabolome in humans
por: Alwashih, Mohammad A., et al.
Publicado: (2017) -
Quality of life in adults with congenital adrenal hyperplasia relates to glucocorticoid treatment, adiposity and insulin resistance: United Kingdom Congenital adrenal Hyperplasia Adult Study Executive (CaHASE)
por: Han, Thang S, et al.
Publicado: (2013) -
Effect of congenital adrenal hyperplasia treated by glucocorticoids on plasma metabolome: a machine-learning-based analysis
por: Nguyen, Lee S., et al.
Publicado: (2020) -
Pharmacogenomic markers of glucocorticoid response in congenital adrenal hyperplasia
por: Botelho Barra, Cristina, et al.
Publicado: (2022) -
SAT-009 Proof of Concept That Corticosterone Has a Higher Therapeutic Index Than Hydrocortisone in Patients with Congenital Adrenal Hyperplasia
por: Kyle, Catriona, et al.
Publicado: (2019)